Search
Corvus Pharmaceuticals Inc
CRVSAdd to Watchlist
13.260USD
+0.070+0.53%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.12BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
8
analysts
Buy
Current Rating
33.143
Target Price
+149.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Corvus Pharmaceuticals Inc
CRVS
8
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Corvus Pharmaceuticals Inc's price target?
Analysts forecast that Corvus Pharmaceuticals Inc's price target is USD 14.00, with the highest forecast at USD 24.00 and the lowest forecast at USD 11.00.
How have Corvus Pharmaceuticals IncCRVS's recent earnings per share performed?
The market expectation was USD -0.15, while Corvus Pharmaceuticals IncCRVS's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Corvus Pharmaceuticals Inc?
Based on the ratings of Corvus Pharmaceuticals Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.